Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Free Cash Flow (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Free Cash Flow readings, the most recent being $386.8 million for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 42.63% to $386.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $780.5 million, a 31.57% increase, with the full-year FY2025 number at $780.5 million, up 31.57% from a year prior.
  • Free Cash Flow hit $386.8 million in Q4 2025 for Neurocrine Biosciences, up from $250.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $386.8 million in Q4 2025 to a low of -$125.8 million in Q1 2023.
  • Median Free Cash Flow over the past 5 years was $116.8 million (2022), compared with a mean of $116.9 million.
  • Biggest five-year swings in Free Cash Flow: skyrocketed 4792.31% in 2022 and later crashed 161.54% in 2023.
  • Neurocrine Biosciences' Free Cash Flow stood at $2.6 million in 2021, then skyrocketed by 4792.31% to $127.2 million in 2022, then rose by 13.13% to $143.9 million in 2023, then surged by 88.46% to $271.2 million in 2024, then surged by 42.63% to $386.8 million in 2025.
  • The last three reported values for Free Cash Flow were $386.8 million (Q4 2025), $250.1 million (Q3 2025), and $89.5 million (Q2 2025) per Business Quant data.